乳腺癌辅助治疗相关心脏毒性防治药物的应用进展  

Research progress of cardioprotection drugs related to adjuvant treatment of breast cancer

作　　者：邱勋思 唐方明 QIU Xunsi;TANG Fangming(The First Clinical School of Guangdong Medical University,Zhanjiang 524200,China;Department of Cardiology,Guangdong Agricultural Reclamation Center Hospital,Zhanjiang 524200,China)

机构地区：[1]广东医科大学第一临床医学院,广东湛江524200 [2]广东省农垦中心医院心内科,广东湛江524200

出　　处：《老年医学研究》2023年第3期57-60,共4页Geriatrics Research

摘　　要：乳腺癌的发病率居于全球女性恶性肿瘤的首位,其相关辅助治疗,如应用蒽环类药物和人表皮生长因子受体2拮抗剂可以大大降低乳腺癌患者的病死率,但它诱发的心脏毒性是乳腺癌幸存者的主要死亡原因。右雷佐生作为铁螯合剂已经被美国食品药品监督管理局批准用于心脏保护;许多临床研究及荟萃分析表明,临床常用的心血管疾病的治疗药物如肾素—血管紧张素—醛固酮系统拮抗剂、β受体阻滞剂和他汀类药物在预防心脏毒性方面具有巨大的潜力;糖尿病治疗药物钠—葡萄糖协同转运蛋白2抑制剂可能通过抑制DNA损伤和铁死亡途径减轻心脏毒性,并成为预防和治疗乳腺癌辅助治疗相关心脏毒性的候选药物。Breast cancer is the most prevalent female malignancy worldwide,its associated adjuvant therapy,just like application of anthracyclines and human epidermal growth factor receptor 2 antagonists,can significantly reduce the morbidity and mortality of breast cancer patients.But its induced cardiotoxicity is the leading cause of death in breast cancer survivors.Dexrazoxane has been approved by the US Food and Drug Administration as an iron chelator for cardioprotection.Many clinical studies and meta-analyses have shown that drugs commonly used clinically for the treatment of cardiovascular disease,like renin-angiotensin-aldosterone system antagonists,β-blockers and statins have great potential for the prevention of cardiotoxicity.Sodium-glucose co-transporter 2 inhibitors,which are used to treat diabetes,may mitigate cardiotoxicity by inhibiting DNA damage and iron death,and become candidate drugs for prevention and treatment of breast cancer associated cardiac toxicity.

关 键 词：心脏毒性 乳腺癌 蒽环类药物 人表皮生长因子受体2拮抗剂 右雷佐生 肾素—血管紧张素—醛固酮系统拮抗剂 β受体阻滞剂 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]